Restore the integrity of FDA regulation.

Jake Auchincloss · Massachusetts · Democratic

oversight impact 0.68 specificity 0.58 extraction confidence 76%

Commitment kind: unknown. Promised action: not established. Promised outcome: not established. Deadline: unknown; not assumed expired.

Contest this claim

Occurrences

Restore the integrity of FDA regulation & modernize clinical trials to compete with China.

Auchincloss committed to restoring the integrity of FDA regulation.

An Update from Your Congressman
primary · official_post · model gpt-5.5

Evidence

unverified · Source version 79849 · locator unknown

"The FDA Commissioner's National Priority Voucher (CNPV) pilot program is being explored as a pathway to dramatically reduce review times for drug and biological product applications and manufacturing or efficacy supplements."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): As of the refreshed FDA program page crawled during the Oct. 3-5, 2026 lookback, the contested CNPV pathway remained active, with listed 2026 approvals and awards; that weighs against treating the FDA-integrity promise as delivered.

unresolved same_term

Commissioner's National Priority Voucher (CNPV) Pilot Program | FDA
secondary · model gpt-5.5 · confidence 82%

Contest this evidence item

unverified · Source version 79851 · locator unknown

"I am hoping to work with the Commissioner of the FDA to help insulate the career scientists at this gold standard agency from political pressures and ideology that is not evidence-driven."

Unverified model/legacy excerpt; not proof. AI summary (separate from source): Auchincloss used a House Energy and Commerce Health Subcommittee hearing to press FDA leadership over political pressure and the CNPV program, showing oversight effort but not enacted or completed restoration of FDA regulatory integrity.

unresolved same_term A for effort

HHRG-119-IF14-Transcript-20250716.pdf
secondary · model gpt-5.5 · confidence 86%

Contest this evidence item

Assessments

No assessments yet.